MAGISTRONI, Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.370
AS - Asia 7.782
EU - Europa 6.822
SA - Sud America 1.022
AF - Africa 186
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 12
Totale 29.227
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.129
SG - Singapore 2.700
CN - Cina 2.063
IT - Italia 1.732
GB - Regno Unito 1.269
DE - Germania 979
HK - Hong Kong 960
VN - Vietnam 746
BR - Brasile 743
SE - Svezia 690
FI - Finlandia 557
RU - Federazione Russa 413
FR - Francia 288
KR - Corea 237
UA - Ucraina 235
IN - India 187
TR - Turchia 150
ID - Indonesia 134
CA - Canada 127
BG - Bulgaria 113
AR - Argentina 110
NL - Olanda 109
JP - Giappone 99
BD - Bangladesh 88
MX - Messico 68
ES - Italia 67
IQ - Iraq 60
CZ - Repubblica Ceca 58
ZA - Sudafrica 56
AT - Austria 38
RO - Romania 37
MA - Marocco 35
PK - Pakistan 35
AE - Emirati Arabi Uniti 34
CL - Cile 34
PL - Polonia 34
PH - Filippine 32
AU - Australia 31
EC - Ecuador 31
VE - Venezuela 31
CO - Colombia 30
LT - Lituania 28
UZ - Uzbekistan 28
MY - Malesia 27
IE - Irlanda 26
BE - Belgio 21
CH - Svizzera 21
IL - Israele 21
IR - Iran 21
JO - Giordania 17
SA - Arabia Saudita 17
TN - Tunisia 17
PE - Perù 15
TW - Taiwan 15
NP - Nepal 14
PY - Paraguay 14
TH - Thailandia 14
AZ - Azerbaigian 13
DZ - Algeria 13
DK - Danimarca 12
EG - Egitto 12
SI - Slovenia 12
DO - Repubblica Dominicana 11
KZ - Kazakistan 11
AL - Albania 10
CR - Costa Rica 10
KE - Kenya 10
PT - Portogallo 10
LB - Libano 9
NG - Nigeria 9
EU - Europa 8
GR - Grecia 8
KG - Kirghizistan 8
BY - Bielorussia 7
MD - Moldavia 7
OM - Oman 7
PA - Panama 7
UY - Uruguay 7
BH - Bahrain 6
BO - Bolivia 6
HR - Croazia 6
PS - Palestinian Territory 6
RS - Serbia 6
EE - Estonia 5
ET - Etiopia 5
MK - Macedonia 5
NO - Norvegia 5
SN - Senegal 5
CG - Congo 4
CI - Costa d'Avorio 4
GE - Georgia 4
HN - Honduras 4
MT - Malta 4
GA - Gabon 3
JM - Giamaica 3
LA - Repubblica Popolare Democratica del Laos 3
MN - Mongolia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
GT - Guatemala 2
Totale 29.179
Salva come PNG Salva come JPEG
Città #
Singapore 1.954
Santa Clara 1.561
Ashburn 1.420
Fairfield 1.170
Hong Kong 932
Chandler 721
San Jose 708
Southend 699
Hefei 675
Woodbridge 632
Houston 546
Helsinki 465
Seattle 444
Wilmington 437
Nyköping 421
Cambridge 376
Jacksonville 357
London 332
Beijing 322
Ann Arbor 285
Dearborn 250
Modena 246
Ho Chi Minh City 227
Council Bluffs 226
Los Angeles 217
Seoul 217
Chicago 202
The Dalles 199
Hanoi 186
New York 175
Dallas 128
San Diego 119
Sofia 110
Princeton 106
Lauterbourg 101
Munich 100
Jakarta 95
Milan 95
Moscow 81
Shanghai 81
São Paulo 77
Tokyo 73
Salt Lake City 70
Eugene 69
Bologna 67
Redwood City 66
Buffalo 64
Orem 63
Rome 57
Frankfurt am Main 48
Izmir 47
Brno 46
Parma 46
Des Moines 44
Buenos Aires 41
Tampa 41
Chennai 40
Phoenix 38
Da Nang 37
Guangzhou 37
Nuremberg 37
Amsterdam 36
Montreal 34
Toronto 32
Columbus 31
Elk Grove Village 30
Boardman 28
Nanjing 27
Atlanta 26
Falls Church 26
Kent 26
Tashkent 26
Warsaw 26
Baghdad 25
Fremont 25
Haiphong 25
San Francisco 24
Brooklyn 23
Bremen 22
Denver 22
Naples 22
Norwalk 22
Rio de Janeiro 22
Turku 22
Stockholm 21
Redondo Beach 20
Lancaster 19
Bari 18
Brussels 18
Dublin 18
Johannesburg 18
Madrid 18
Perugia 18
Vienna 18
Wuhan 18
Mexico City 17
Paris 17
Reggio Emilia 17
Belo Horizonte 16
Boston 16
Totale 19.615
Salva come PNG Salva come JPEG
Nome #
CD133 and CD24 expression in renal tissue of patients affected by autosomal dominant polcystic kidney disease 398
Approccio pratico alla terapia del paziente affetto da Rene Policistico Autosomico Dominante 396
Interstitial fluid obtained from kidney biopsy as new source of renal biomarkers 379
Plasma exchange in acute and chronic hyperviscosity syndrome: a rheological approach and guidelines study 375
Identification and Characterization of New Proteins in Podocyte Dysfunction of Membranous Nephropathy by Proteomic Analysis of Renal Biopsy 357
Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy? 356
Pregnancy and progression of IgA nephropathy: results of an Italian multicenter study 355
Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens 352
APOE MODENA : A NOVEL APOE MUTANT CAUSING LIPOPROTEIN GLOMERULOPATHY 351
Tolvaptan in patients with autosomal dominant polycystic kidney disease 351
The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition 351
GREASE II. A phase II randomized, 12-month, parallel-group, superiority study to evaluate the efficacy of a Modified Atkins Diet in Autosomal Dominant Polycystic Kidney Disease patients 341
Confidence Calibration for Deep Renal Biopsy Immunofluorescence Image Classification 333
The definition of chronic kidney disease in a context of aging population 328
Evaluation of the Classification Accuracy of the Kidney Biopsy Direct Immunofluorescence through Convolutional Neural Networks 328
Identification and characterization of a new autoimmune protein in membranous nephropathy by immunoscreening of a renal cDNA library 326
New developments in the genetics, pathogenesis, and therapy of IgA nephropathy 319
A pilot study to evaluate Tolerability and Safety of a Modified Atkins Diet in ADPKD patients 319
Automated Prediction of Kidney Failure in IgA Nephropathy with Deep Learning from Biopsy Images 314
Hypokalemia in Patients with COVID-19 309
Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis 304
Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy 300
Lipoprotein glomerulopathy associated with a mutation in apolipoprotein e 292
Corticosteroids in IgA nephropathy: A retrospective analysis from the VALIGA study 286
Comparison of Total Kidney Volume Quantification Methods in Autosomal Dominant Polycystic Disease for a Comprehensive Disease Assessment 286
I polimorfismi del gene dell’enzima di conversione dell’angiotensina (ACE) nel rene policistico autosomico dominante (ADPKD) 286
COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine 285
Peritoneal dialysis in the time of coronavirus disease 2019 285
Tonsillectomy in a European Cohort of 1,147 Patients with IgA Nephropathy 284
Deciphering Variability of PKD1 and PKD2 in an Italian Cohort of 643 Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) 284
Unified criteria for ultrasonographic diagnosis of ADPKD 282
ADPKD current management and ongoing trials 280
Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): A case report 277
Defective glycolysis and the use of 2-deoxy-d-glucose in polycystic kidney disease: from animal models to humans 277
Il rene policistico autosomico dominante (ADPKD): aspetti genetico-molecolari, clinici ed epidemiologici nella provincia di Modena. 276
Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease 275
Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease 268
Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis 262
Advances in genetics of Immunoglobulin A Nephropathy. 258
Acid base disorders in patients with COVID-19 258
A validated model of disease progression in IgA nephropathy 257
Autosomal dominant polycystic kidney disease: from genes to cilium. 254
Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens 253
Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments 253
Proteomic analysis of urine from proteinuric patients shows a proteolitic activity directed against albumin 251
[Screening for cerebral aneurysms in the ADPKD population: mandatory or potentially harmful?] 247
Genome-wide association study identifies susceptibility loci for IgA nephropathy 246
#5187 GREASE II: A PHASE II RANDOMIZED, 24-MONTH, PARALLEL-GROUP, SUPERIORITY STUDY TO EVALUATE THE EFFICACY OF A KETOGENIC DIET IN ADPKD PATIENTS 243
Geometry-independent assessment of renal volume in polycystic kidney disease from magnetic resonance imaging 243
Epidermal growth factor receptor polymorphism and autosomal dominant polycystic kidney disease 243
Il Registro Italiano del Rene PolicisticoAutosomico Dominante 242
Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy 241
HEMOREOLOGIC PROFILE OF KIDNEY TRANSPLANT RECIPIENTS: A ROLE IN CARDIOVASCULAR RISK? 240
Methicillin-Resistant Staphylococcus aureus Peritonitis due to Hematogenous Dissemination from Central Venous Catheter in a Maintenance Dialysis Patient 239
Genetic variation of DKK3 may modify renal disease severity in ADPKD 236
Trattato di Medicina Interna : Le Sindromi Renali. 234
Interstitiome: a novel proteomic discipline applied to renal biopsy 233
Oxalate Nephropathy Caused by Excessive Vitamin C Administration in 2 Patients With COVID-19 233
Evaluation of coronary artery disease by multislice spiral computed tomography in dialysis patients 232
COVID-19 Rapid Antigen Test Screening in Patients on Hemodialysis 230
Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy 230
Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36 227
Screening of a kidney cDNA library for the identification of autoimmune proteins from serum of membranous nephropathy patients. 227
Urine Proteome Analysis May Allow Non-Invasive Differential Diagnosis of Diabetic Nephropathy 225
Monoclonal antibodies in nephrology: a delicate balance between curative potential, evidence of effectiveness, and toxicity 225
Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease 224
Reliability of Total Renal Volume Computation in Polycystic Kidney Disease From Magnetic Resonance Imaging 221
The underlying cause of kidney disease is often unknown in dialysis patients: a possible genomic approach 217
Comment on the paper: 'novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease' 216
The MEST score provides earlier risk prediction in lgA nephropathy 214
Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial 211
Combining telemedicine and in-person visits to deliver care to patients with severe chronic kidney disease (CKD): Lessons learned from COVID-19 209
TRPP2 dysfunction decreases ATP-evoked calcium, induces cell aggregation and stimulates proliferation in T lymphocytes 208
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy 207
Long-term effects of COVID-19 in a patient on maintenance dialysis 207
Clinical Predictors of Nondiabetic Kidney Disease in Patients with Diabetes: A Single-Center Study 206
Primary IgA nephropathy is more severe in TGF-beta1 high secretor patients. 205
One-year persistence of neutralizing anti-SARS-CoV-2 antibodies in dialysis patients recovered from COVID-19 204
Artificial intelligence in glomerular diseases 203
SARS-CoV-2 infection in dialysis patients in northern Italy: A single-centre experience 199
Clinical Presentation, Renal Histopathological Findings, and Outcome in Patients with Monoclonal Gammopathy and Kidney Disease 199
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool 195
Mycophenolate mofetil plus steroids compared to steroids alone in IgA nephropathy: a retrospective study 190
MALATTIE DEL RENE, DELLE VIE URINARIE E DELL'APPARATO GENITALE MASCHILE : Le Nefropatie Glomerulari: glomerulonefriti primitive; glomerulonefriti secondarie 187
Incidence, risk factors and outcome of acute kidney injury (AKI) in patients with COVID-19 185
Hybrid dialysis: A promising strategy to reduce hospital access during the SARS-CoV-2 pandemic 184
Immunosuppressive therapy reduction and early post-infection graft function in kidney transplant recipients with COVID-19 184
The frail world of haemodialysis patients in the COVID-19 pandemic era: a systematic scoping review 181
AKI in hospitalized patients with COVID-19: a single-center experience 181
Monoclonal B lymphocytosis in a kidney transplant recipient 180
PATIENT AND TECHNIQUE SURVIVAL ON PERITONEAL DIALYSIS: A RETROSPECTIVE STUDY 175
Risk of bleeding after percutaneous native kidney biopsy in patients receiving low-dose aspirin: a single-center retrospective study 174
Clinical diagnosis of Autosomal Dominant Polycystic Kidney Disease 171
Weekly Rapid Antigen Test Screening for COVID-19 in Patients on Hemodialysis 168
[Diagnosis in Polycystic Kidney Disease] 165
[Genetics and genetic counseling] 164
Erratum: The Role of the Renin-Angiotensin System in Severe Acute Respiratory Syndrome-CoV-2 Infection (Journal of Physical Chemistry DOI: 10.1159/000507914) 163
Erratum: SARS-CoV-2 infection in dialysis patients in northern Italy: A single-centre experience (Clinical Kidney Journal (2020) 13:3 (334-339) DOI: 10.1093/ckj/sfaa084) 163
A Review of the Imaging Techniques for Measuring Kidney and Cyst Volume in Establishing Autosomal Dominant Polycystic Kidney Disease Progression 162
Central delivery of acid concentrate for haemodialysis: a single center experience 160
Totale 25.209
Salva come PNG Salva come JPEG
Categoria #
all - tutte 116.124
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 116.124
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021744 0 0 0 0 0 0 0 0 0 351 255 138
2021/20222.342 180 206 223 166 100 131 130 138 260 189 371 248
2022/20232.439 234 247 209 211 215 332 95 249 258 57 142 190
2023/20241.848 101 113 127 227 280 174 179 227 56 64 105 195
2024/20255.698 148 100 113 426 1.060 954 349 308 640 317 602 681
2025/202610.138 754 456 895 1.193 1.846 771 1.562 550 1.150 961 0 0
Totale 29.539